# A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Study · id `cardio:ct-nct01516541` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01516541](<https://clinicaltrials.gov/study/NCT01516541>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01516541

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2220 participants.

## Technical summary

Registry record NCT01516541. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2220 participants (enrolled count; ClinicalTrials.gov record NCT01516541, source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01516541, source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)
- Primary completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01516541, source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)
- Completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01516541, source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; China; Czechia; Denmark; France; Hungary; Mexico; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT01516541, source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01516541-2016-11-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
- Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
- Intervention (Other): Background care
- Intervention (Drug): Placebo
- Intervention (Drug): dalcetrapib
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 562fb53e0259fd9470bd568b4d42ec9293c397609bcc11a4a0ffd3cba39bea2f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
